Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

An elevated pro-inflammatory cytokine response is linked to development of amphotericin B-induced nephrotoxicity.

Chai LY, Netea MG, Tai BC, Khin LW, Vonk AG, Teo BW, Schlamm HT, Herbrecht R, Donnelly JP, Troke PF, Kullberg BJ.

J Antimicrob Chemother. 2013 Jul;68(7):1655-9. doi: 10.1093/jac/dkt055. Epub 2013 Apr 3.

PMID:
23557927
2.

Are there risk factors for acute renal failure in adult patients using deoxycholate amphotericin B?

Tuon FF, Koenig F, Jacometto D, Rocha JL.

Rev Iberoam Micol. 2013 Jan 3;30(1):21-4. doi: 10.1016/j.riam.2012.09.003. Epub 2012 Sep 17.

PMID:
22995903
4.

Lipid formulations of amphotericin B: clinical efficacy and toxicities.

Wong-Beringer A, Jacobs RA, Guglielmo BJ.

Clin Infect Dis. 1998 Sep;27(3):603-18. Review.

PMID:
9770163
5.

Amphotericin B nephrotoxicity.

Deray G.

J Antimicrob Chemother. 2002 Feb;49 Suppl 1:37-41. Review.

PMID:
11801579
6.
7.

Characterizing and predicting amphotericin B-associated nephrotoxicity in bone marrow or peripheral blood stem cell transplant recipients.

Gubbins PO, Penzak SR, Polston S, McConnell SA, Anaissie E.

Pharmacotherapy. 2002 Aug;22(8):961-71.

PMID:
12173799
8.
9.

Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex.

Wade RL, Chaudhari P, Natoli JL, Taylor RJ, Nathanson BH, Horn DL.

Diagn Microbiol Infect Dis. 2013 Jul;76(3):361-7. doi: 10.1016/j.diagmicrobio.2013.04.001.

PMID:
23774005
10.
11.
12.

Experience with community-based amphotericin B infusion therapy.

Malani PN, Depestel DD, Riddell J, Bickley S, Klein LR, Kauffman CA.

Pharmacotherapy. 2005 May;25(5):690-7.

13.

Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries.

Ullmann AJ, Sanz MA, Tramarin A, Barnes RA, Wu W, Gerlach BA, Krobot KJ, Gerth WC; Longitudinal Evaluation of Antifungal Drugs (LEAD I) Investigators.

Clin Infect Dis. 2006 Aug 15;43(4):e29-38. Epub 2006 Jul 10.

PMID:
16838223
14.
15.

Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis.

Wingard JR, Kubilis P, Lee L, Yee G, White M, Walshe L, Bowden R, Anaissie E, Hiemenz J, Lister J.

Clin Infect Dis. 1999 Dec;29(6):1402-7.

PMID:
10585786
16.

Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients.

Miller CB, Waller EK, Klingemann HG, Dignani MC, Anaissie EJ, Cagnoni PJ, McSweeney P, Fleck PR, Fruchtman SM, McGuirk J, Chao NJ.

Bone Marrow Transplant. 2004 Mar;33(5):543-8.

PMID:
14730342
17.

Acute renal failure with amphotericin B in lipid emulsion.

Gales MA, Gales BJ, Alford KM.

Ann Pharmacother. 1996 Sep;30(9):1036. No abstract available.

PMID:
8876871
18.

Risk factors of amphotericin B toxicty in the nonneonatal pediatric population.

Dutta A, Palazzi DL.

Pediatr Infect Dis J. 2012 Sep;31(9):910-4. doi: 10.1097/INF.0b013e31825d649a.

PMID:
22581225
20.

Proteinuria lowers the risk of amphotericin B-associated hypokalaemia.

Mohan S, Ahmed S, Alimohammadi B, Jaitly M, Cheng JT, Pogue VA.

J Antimicrob Chemother. 2007 Sep;60(3):690-3. Epub 2007 Jun 27.

PMID:
17597057

Supplemental Content

Support Center